[{"orgOrder":0,"company":"Neuracle Genetics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NG101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Neuracle Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuracle Genetics \/ Ora, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Neuracle Genetics \/ Ora, Inc"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GVB-2001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"iView Therapeutics \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"7","companyTruncated":"iView Therapeutics \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OTX-CSI","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Tianjin Medical University Eye Hospital | The First Affiliated Hospital of Soochow University | Peking Union Medical College Hospital | Beijing Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Tianjin Medical University Eye Hospital | The First Affiliated Hospital of Soochow University | Peking Union Medical College Hospital | Beijing Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Tianjin Medical University Eye Hospital | The First Affiliated Hospital of Soochow University | Peking Union Medical College Hospital | Beijing Hospital"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Series C Financing","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ RA Capital Management"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Series D Financing","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Sands Capital","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Sands Capital"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"The First Affiliated Hospital of Soochow University | Tianjin Medical University Eye Hospital | Peking Union Medical College Hospital | The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ The First Affiliated Hospital of Soochow University | Tianjin Medical University Eye Hospital | Peking Union Medical College Hospital | The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ The First Affiliated Hospital of Soochow University | Tianjin Medical University Eye Hospital | Peking Union Medical College Hospital | The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Tianjin Medical University Eye Hospital | Peking Union Medical College Hospital | The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Tianjin Medical University Eye Hospital | Peking Union Medical College Hospital | The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Tianjin Medical University Eye Hospital | Peking Union Medical College Hospital | The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SKG0106","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Skyline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Skyline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Skyline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avirmax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABI-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Avirmax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Avirmax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avirmax \/ Inapplicable"},{"orgOrder":0,"company":"Avirmax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ABI-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Avirmax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Avirmax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avirmax \/ Inapplicable"},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SKG0106","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Skyline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Skyline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Skyline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perceive Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VOY-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perceive Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Perceive Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perceive Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perceive Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VOY-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perceive Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Perceive Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perceive Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Anti-Vegf Humanized Monoclonal Antibody","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NFS-02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EyeBio","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"EyeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Inapplicable"},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":3,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Merck & Co"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NPI-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Kentucky","sponsor":"Inflammasome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SOM-401","moa":"Nucleoside reverse transcriptase","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"University of Kentucky","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant, Sustained Release","sponsorNew":"University of Kentucky \/ Inflammasome Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Kentucky \/ Inflammasome Therapeutics"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NPI-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NPI-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Series A Financing","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Aflibercept","moa":"||Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Aflibercept","moa":"||Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGFR3","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGFR3","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGFR3","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"EC-104","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Eclipse Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eclipse Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BAT5906","moa":"HER2","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AR-14034","moa":"EGFR","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAR402663","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EYE201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Solution","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":3,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Merck & Co"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KH658","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Origen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Chengdu Origen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Origen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Exonate","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Exonate \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ Novotech"},{"orgOrder":0,"company":"Exonate","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Exonate \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ Johnson & Johnson"},{"orgOrder":0,"company":"Exonate","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Exonate \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"NexThera","sponsor":"KCRN Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"KOSOVO","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"NT-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NexThera \/ KCRN Research","highestDevelopmentStatusID":"7","companyTruncated":"NexThera \/ KCRN Research"},{"orgOrder":0,"company":"NexThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"KOSOVO","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"NT-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NexThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexThera \/ Inapplicable"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"National University of Malaysia \/ Santen Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"National University of Malaysia \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Zhejiang University | Hangzhou Yuansheng Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Zhejiang University | Hangzhou Yuansheng Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Zhejiang University | Hangzhou Yuansheng Biotechnology"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OpRegen","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OpRegen RPE Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Claris Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"CSB-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Claris Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Claris Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Claris Bio \/ Inapplicable"},{"orgOrder":0,"company":"Claris Bio","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Oremepermin Alpha","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Claris Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Ophthalmic Solution","sponsorNew":"Claris Bio \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Claris Bio \/ Organovo Holdings"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TRS01","moa":"NFkB","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LEV102","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Levation Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Livionex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"Lead; Iron; Manganese cation","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Livionex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Livionex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Livionex \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Whitecap Biosciences","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"WB007","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Whitecap Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Whitecap Biosciences \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"7","companyTruncated":"Whitecap Biosciences \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"TRS01","moa":"NFkB","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsier Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Pharma \/ Undisclosed"},{"orgOrder":0,"company":"iVeena","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"iVeena \/ Glaukos","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Glaukos"},{"orgOrder":0,"company":"iVeena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"iVeena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Inapplicable"},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ National Eye Institute"},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"IVMED-85","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ National Eye Institute"},{"orgOrder":0,"company":"Hai Yen Eye Care","sponsor":"Brien Holden Vision Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BHVI1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Hai Yen Eye Care","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Hai Yen Eye Care \/ Brien Holden Vision Institute","highestDevelopmentStatusID":"7","companyTruncated":"Hai Yen Eye Care \/ Brien Holden Vision Institute"},{"orgOrder":0,"company":"Seinda Pharmaceutical Guangzhou Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SY-201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Seinda Pharmaceutical Guangzhou Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Seinda Pharmaceutical Guangzhou Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Seinda Pharmaceutical Guangzhou Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Theratocular Biotek Co.","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TO-O-1001","moa":"LSD1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Theratocular Biotek Co.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Theratocular Biotek Co. \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Theratocular Biotek Co. \/ Novotech"},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KH658","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Origen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Chengdu Origen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Origen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kiora Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NexThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"KOSOVO","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"NT-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NexThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexThera \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NFS-02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Future Medicine","sponsor":"Futuremedicine Australia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"FM101","moa":"CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Future Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Future Medicine \/ Futuremedicine Australia","highestDevelopmentStatusID":"7","companyTruncated":"Future Medicine \/ Futuremedicine Australia"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"National Institutes of Health | National Eye Institute | Regenerative Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Luxa Biotechnology \/ National Institutes of Health | National Eye Institute | Regenerative Research Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ National Institutes of Health | National Eye Institute | Regenerative Research Foundation"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Luxa Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Luxa Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Refreshgene Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RRG001","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Refreshgene Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Shanghai Refreshgene Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Refreshgene Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Jiayin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EXG102-031","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Jiayin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Jiayin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiayin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.67000000000000004,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"EyeDNA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAV2\/5-hPDE6B","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeDNA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"EyeDNA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EyeDNA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Subretinal Injection","sponsorNew":"Coave Therapeutics \/ Seroba Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Seroba Life Sciences"},{"orgOrder":0,"company":"Eyestem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Eyestem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CNGB3","moa":"CNGB3","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VV-14295","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Kriya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kriya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zifibancimig","moa":"Angiopoietin-2 (ANGPT2)","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Canyon City Eyecare","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EXP039","moa":"CD19\/20","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Canyon City Eyecare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canyon City Eyecare \/ Nevakar","highestDevelopmentStatusID":"7","companyTruncated":"Canyon City Eyecare \/ Nevakar"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"7","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KH631","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Origen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Origen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Origen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NFS-02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OpCT-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV2tYF-PR1.7-hCNGB3","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Colorado Eye Consultants","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Colorado Eye Consultants","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Colorado Eye Consultants \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Colorado Eye Consultants \/ Inapplicable"},{"orgOrder":0,"company":"iVeena","sponsor":"Codet Vision Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IVMED-80","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"iVeena \/ Codet Vision Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Codet Vision Institute"},{"orgOrder":0,"company":"iVeena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IVMED-85","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iVeena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Inapplicable"},{"orgOrder":0,"company":"TearSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"Lacritin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"TearSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TearSolutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TearSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Boston Sight","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Boston Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Boston Sight \/ Allergan","highestDevelopmentStatusID":"7","companyTruncated":"Boston Sight \/ Allergan"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AGN-241622","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AGN-193408","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Natureceuticals Sdn Bhd","sponsor":"Ministry of Agriculture, Malaysia | Quest International University | Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Lanctos 75 Standardized Orthosiphon Stamineus Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Natureceuticals Sdn Bhd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natureceuticals Sdn Bhd \/ Ministry of Agriculture, Malaysia | Quest International University | Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia","highestDevelopmentStatusID":"7","companyTruncated":"Natureceuticals Sdn Bhd \/ Ministry of Agriculture, Malaysia | Quest International University | Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia"},{"orgOrder":0,"company":"JeniVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JV-GL1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"JeniVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JeniVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JeniVision \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BI765128","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CBT-009","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cloudbreak Therapeutics \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Cloudbreak Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Kinezodianone R-HCI","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires Thea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Laboratoires Thea \/ Inapplicable"},{"orgOrder":0,"company":"Sinocelltech Ltd.","sponsor":"Tianjin Medical University Eye Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SCT520FF","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech Ltd. \/ Tianjin Medical University Eye Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech Ltd. \/ Tianjin Medical University Eye Hospital"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7446603","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Levation Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KH631","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Chengdu Origen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Origen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chengdu Origen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"iVeena","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"IVMED-85","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"iVeena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Undisclosed"},{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tropicamide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unither Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Unither Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biojiva LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BRX011","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Biojiva LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biojiva LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biojiva LLC \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"KB801","moa":"NGF","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"VG801","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViGeneron \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ViGeneron \/ Undisclosed"},{"orgOrder":0,"company":"Eyestem","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"Eyecyte-RPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Eyestem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Undisclosed"}]
Find Ophthalmology Drugs in Phase I/II Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
